Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 6.32 (+0.18), BIIB: 269.16 (-10.72), ZIOP: 10.92 (+0.32), BMRN: 102.69 (+1.97), PCYC: 261.25 (+1.70), CLDN: 1.12 (+0.03), HSP: 89.95 (-0.01), HRTX: 25.72 (-0.93), ANTH: 6.12 (+0.12), SHPG: 200.90 (-1.85), CLLS: 26.61 (-0.16), RTRX: 20.22 (+1.07), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), AAVL: 8.48 (+0.01), SNY: 48.75 (+0.03), PFE: 33.24 (+0.15), SLXP: 172.96 (+0.15), GSK: 40.22 (+0.06), CELG: 117.38 (-0.59), ISIS: 43.24 (+0.86), TARO: 148.37 (-0.08), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
BNP Paribas notify of 4.8% shareholding in Galapagos
GlobeNewswire - Fri May 01, 11:06AM CDT
Galapagos NV (Euronext: GLPG) received a transparency notification from BNP Paribas.
GLPG: 44.35 (+0.81)
Galapagos Moves Towards RA Deal But A Dark Horse Remains On The Horizon
EP Vantage - Seeking Alpha - Thu Apr 16, 3:57PM CDT
Galapagos ’ ( OTC:GLPGF , OTCPK:GLPYY ) oral rheumatoid arthritis drug GLPG0634 has cleared the first obstacle in the path to a full-blown licensing deal with AbbVie (NYSE: ABBV ) , hitting the primary endpoint of a crucial phase IIb trial....
Galapagos to list ADSs on Nasdaq
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:35AM CDT
Galapagos JAK-1 inhibitor successful in Phase 2 rheumatoid arthritis study
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:17PM CDT
Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015
GlobeNewswire - Fri Mar 27, 1:42PM CDT
Galapagos NV (Euronext:GLPG) has the honor to invite the Shareholders, Warrant Holders, Directors and Statutory Auditor of the Company to the Annual Shareholders' Meeting that will be held on Tuesday 28 April 2015 at 2:00 p.m. (CET) at the registered office of the Company.
GLPG: 44.35 (+0.81)
Galapagos and Janssen part ways in inflammation alliance
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:58AM CDT
JNJ: 95.37 (+0.29)
Galapagos' (GLPYY) CEO Onno van de Stolpe on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 06, 11:49AM CST
Galapagos earns milestone from AbbVie
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:09AM CST
ABBV: 55.64 (-0.40)
Galapagos and Janssen divorce on IBD collaboration
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 6:48AM CST
JNJ: 95.37 (+0.29)